ERBB2 and gastric cancer: For instance, the RC48-C008 study is a clinical trial of Vidextus in the field of gastric cancer, incorporating 125 patients with advanced metastatic gastric cancer who have previously undergone ≥ 2 lines of treatment, including patients with HER2 IHC 2 + and 3 + expressions.